|Mr. Brian O'Callaghan||Chief Exec. Officer||4.29M||N/A||1969|
|Dr. Ernest Loumaye||Co-Founder & Director||1M||N/A||1952|
|Mr. David Renas||Chief Financial Officer||N/A||N/A||1964|
|Dr. Jean-Pierre Gotteland Ph.D.||Chief Scientific Officer and Head of R&D||N/A||N/A||1965|
|Mr. Fabien Lefebvre de Ladonchamps||Chief Admin. Officer||N/A||N/A||1979|
|Mr. Mario Vincent Corso||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Ms. Delphine Renaud||Personal Assistant to the CSO and Head of R&D||N/A||N/A||N/A|
|Mr. Wim Souverijns||Chief Commercial Officer||N/A||N/A||1970|
|Dr. Elizabeth Ijeoma Onyemelukwe Garner||Chief Medical Officer||N/A||N/A||1968|
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.